News | June 07, 2023
JB Pharma completes 1 year of its identity launch
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
The company has extended its full co-operation and support to the officials of the Income Tax Department
The new Biolys provides higher concentration of L-lysine
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
One thousand times more soluble than L-cystine at neutral pH
Subscribe To Our Newsletter & Stay Updated
